FGF21/sTGFBR2 or FGF21 alone was sufficient to reduce hepatic steatosis in lipodystrophic mice, and dual FGF21/sTGFBR2 therapy reduced cortical bone volume fraction. Here, FGF21 is linked to fatty liver disease.